Dexcom (NSDQ:DXCM) and Fitbit (NYSE:FIT) have partnered to develop and market continuous glucose monitoring technology for people with diabetes, the companies announced today.
The companies plan to integrate Dexcom’s CGM data with Fitbit’s new smartwatch, the Fitbit Ionic, so CGM users on Android or iOS devices can see their activity and glucose levels on their wrists.
“The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days, coupled with Dexcom’s market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,” Fibit CEO James Park said in prepared remarks. “With Ionic, we are focused on driving positive health outcomes and more health focused tools, and this collaboration is a wonderful example of how we plan to bring that vision to our users.”
Get the full story on our sister site Drug Delivery Business.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.